AI Article Synopsis
- The study analyzed the effectiveness of cytotoxic T- and B-cell crossmatch tests prior to allogeneic stem cell transplantation (allo-SCT) in 157 patients from 2000 to 2005.
- Only 11 out of the patients rejected their grafts, with T-cell crossmatches showing low sensitivity (9%) but high specificity (97%), while B-cell crossmatches had better sensitivity (36%) and lower specificity (86%).
- Ultimately, the findings suggest that positive cytotoxic crossmatches before SCT do not reliably predict graft rejection or survival outcomes.
Article Abstract
The predictive value of cytotoxic crossmatch analysis before allo-SCT remains unclear. We retrospectively analyzed the clinical impact of cytotoxic T- and B-cell crossmatch testing before allo-SCT between January 2000 and June 2005. Cytotoxic crossmatches were performed in 157 patients receiving stem cells from matched unrelated donors or an HLA-A, -B or -DRB1 allele mismatched graft. Ninety patients are still alive. Eleven patients rejected their grafts. One of 11 patients with rejection was positive in a T-cell crossmatch before allo-SCT and 4 of 11 in B-cell crossmatches. T-cell crossmatches showed a sensitivity of 9% and a specificity of 97% compared with 36 and 86% for B-cell crossmatches. Positive T- and/or B-crossmatch before SCT had no predictive value for survival in this study as compared with patients with a negative crossmatch. In conclusion, the pretransplant cytotoxic T- and/or B-crossmatch is a poor predictor of rejection after allo-SCT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/bmt.2009.144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of access and outcomes of kidney transplantation through the reforms of the Swiss organ allocation system.
Front Public Health
January 2025
Transplant Immunology Unit, Geneva University Hospitals, Geneva, Switzerland.
Introduction: The Swiss allocation system for kidney transplantation has evolved over time to balance medical urgency, immunological compatibility, and waiting time. Since the introduction of the transplantation law in 2007, which imposed organ allocation on a national level, the algorithm has been optimized. Initially based on waiting time, HLA compatibility, and crossmatch performed by cell complement-dependent cytotoxicity techniques, the system moved in 2012 to a score including HLA compatibility, waiting time, anti-HLA antibodies detected by the Luminex technology, and a virtual crossmatch.
View Article and Find Full Text PDFImlifidase in Highly Sensitized Kidney Transplant Recipients With a Positive Crossmatch Against a Deceased Donor.
Kidney Int Rep
October 2024
Bordeaux University Hospital, Department of Nephrology, Transplantation, Dialysis and Apheresis, UMR-CNRS5164 Immunoconcept, University of Bordeaux, Bordeaux, France.
Article Synopsis
- Imlifidase is used for desensitizing highly sensitized adult kidney transplant candidates with a positive crossmatch against deceased donors, and results from the first 9 patients are reported after at least 3 months of follow-up.
- All 9 patients had been on dialysis for an average of over 10 years, and after treatment with imlifidase, all patients showed negative results for donor-specific antibodies (DSAs) that could have restricted their transplant eligibility.
- The study concludes that imlifidase appears to be effective and safe for desensitization in these patients, with no graft losses or deaths reported, although some patients did experience infections and DSA rebounds.
Introduction of the donor centre virtual crossmatch in Eurotransplant.
HLA
August 2024
Eurotransplant International Foundation, Leiden, the Netherlands.
On 24 January 2023, Eurotransplant has introduced the virtual crossmatch for kidney and pancreas allocation as a better alternative for the physical Complement Dependent Cytotoxicity (CDC) crossmatches at the donor centre, which were associated with a longer cold ischaemia time and false positive reactions. For the time being, the physical CDC crossmatch at the recipient centre will remain in place as the final histocompatibility check. While Eurotransplant is certainly not the first organ allocation organisation to introduce virtual crossmatching, several novel aspects have been introduced, such as calculation of the virtual panel reactive antibody (vPRA) on 11 loci at the second-field level in addition to the serological broad and split level, electronic HLA typing data transmission using Histoimmunogenetics Markup Language (HML) file format, and the actual virtual crossmatch based on ambiguous, second-field HLA typing of the donor on all 11 loci.
View Article and Find Full Text PDFSuccessful Desensitization with Imlifidase and Daratumumab in a Highly Immunized, Crossmatch Positive, Blood Group-Incompatible Living-Donor Re-Transplant Recipient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome.
Transfus Med Hemother
June 2024
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Article Synopsis
- The text discusses the challenges faced by highly sensitized patients in receiving kidney transplants, noting that their outcomes are typically poorer and they face longer wait times if not prioritized.
- A successful case study is presented involving a 35-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome who underwent an incompatible living donor kidney transplant.
- The treatment strategy utilized innovative therapies, including daratumumab and imlifidase, leading to successful transplant outcomes despite initial complications such as delayed graft function and acute tubular necrosis.
Analysis of immunogenetics interlaboratory comparisons' success rates. External quality assurance system of the Spanish Society for Immunology GECLID-SEI.
Front Genet
April 2024
Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain.
Background: For many years, transplantation outcomes were uncertain and not hopeful, until histocompatibility testing spread. Common criteria for histocompatibility assays and communications' improvement allowed an efficient organ sharing system. The possibility of organ exchanges is closely linked to the importance of interlaboratory comparisons for histocompatibility and immunogenetics methods.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!